Wakix Hits Record High Prescription Demand in Q2
Harmony Biosciences Holdings Inc reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix. Second-quarter growth was up 25% versus the same period in 2022, primarily attributed to strong commercial sales of Wakix driven by continued organic demand tapping into a large market opportunity (approximately 80,000 patients are diagnosed with…